[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN113966331A - 含脲结构的三芳环化合物及其应用 - Google Patents

含脲结构的三芳环化合物及其应用 Download PDF

Info

Publication number
CN113966331A
CN113966331A CN202180002962.9A CN202180002962A CN113966331A CN 113966331 A CN113966331 A CN 113966331A CN 202180002962 A CN202180002962 A CN 202180002962A CN 113966331 A CN113966331 A CN 113966331A
Authority
CN
China
Prior art keywords
radical
alkyl
substituted
tri
aromatic ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180002962.9A
Other languages
English (en)
Other versions
CN113966331B (zh
Inventor
蔡倩
张章
吴开富
肖国荣
何蕊
黄晶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan University
Original Assignee
Jinan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan University filed Critical Jinan University
Publication of CN113966331A publication Critical patent/CN113966331A/zh
Application granted granted Critical
Publication of CN113966331B publication Critical patent/CN113966331B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供了一种具有式(I)所示结构的含脲结构的三芳环化合物或其药学上可接受的盐或其立体异构体或其前药分子或其代谢产物或其溶剂化物，该类化合物可以有效地抑制激酶，尤其是FLT3和RET激酶，进而调节下游的多条通路的激活，可以用于制备防治RET激酶、FLT3激酶和/或Kit激酶相关的多种疾病的药物，比如白血病、肿瘤。

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN202180002962.9A 2020-03-11 2021-03-05 含脲结构的三芳环化合物及其应用 Active CN113966331B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020101661011 2020-03-11
CN202010166101 2020-03-11
PCT/CN2021/079354 WO2021180008A1 (zh) 2020-03-11 2021-03-05 含脲结构的三芳环化合物及其应用

Publications (2)

Publication Number Publication Date
CN113966331A true CN113966331A (zh) 2022-01-21
CN113966331B CN113966331B (zh) 2024-04-12

Family

ID=77670992

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180002962.9A Active CN113966331B (zh) 2020-03-11 2021-03-05 含脲结构的三芳环化合物及其应用

Country Status (2)

Country Link
CN (1) CN113966331B (zh)
WO (1) WO2021180008A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115772167A (zh) * 2021-09-08 2023-03-10 暨南大学 含脲结构的化合物及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025502748A (ja) 2021-12-30 2025-01-28 バイオメア フュージョン，インコーポレイテッド Ｆｌｔ３の阻害剤としてのピラジン化合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1544420A (zh) * 1997-12-22 2004-11-10 用取代杂环脲抑制raf激酶
CN101448843A (zh) * 2006-03-17 2009-06-03 埃姆比特生物科学公司 用于疾病治疗的咪唑并噻唑化合物
CN101835472A (zh) * 2007-11-08 2010-09-15 埃姆比特生物科学公司 N-(5-叔丁基-异噁唑-3-基)-N′-{4-[7-(2-吗啉-4-基-乙氧基)咪唑并[2,1-b][1,3]苯并噻唑-2-基]苯基}脲治疗增殖性疾病的给药方法
US20120225880A1 (en) * 2011-03-04 2012-09-06 National Health Research Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
CN107459521A (zh) * 2016-06-03 2017-12-12 合肥中科普瑞昇生物医药科技有限公司 Flt3激酶的新型抑制剂及其用途
CN110437220A (zh) * 2018-07-13 2019-11-12 暨南大学 三氮唑类化合物及其应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1544420A (zh) * 1997-12-22 2004-11-10 用取代杂环脲抑制raf激酶
CN101448843A (zh) * 2006-03-17 2009-06-03 埃姆比特生物科学公司 用于疾病治疗的咪唑并噻唑化合物
CN101835472A (zh) * 2007-11-08 2010-09-15 埃姆比特生物科学公司 N-(5-叔丁基-异噁唑-3-基)-N′-{4-[7-(2-吗啉-4-基-乙氧基)咪唑并[2,1-b][1,3]苯并噻唑-2-基]苯基}脲治疗增殖性疾病的给药方法
US20120225880A1 (en) * 2011-03-04 2012-09-06 National Health Research Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
CN107459521A (zh) * 2016-06-03 2017-12-12 合肥中科普瑞昇生物医药科技有限公司 Flt3激酶的新型抑制剂及其用途
CN110437220A (zh) * 2018-07-13 2019-11-12 暨南大学 三氮唑类化合物及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAIFU WU ET AL.: "Discovery of 3,5-diaryl-1H-pyrazol-based ureas as potent RET inhibitors", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》, vol. 251, pages 115237 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115772167A (zh) * 2021-09-08 2023-03-10 暨南大学 含脲结构的化合物及其应用

Also Published As

Publication number Publication date
WO2021180008A1 (zh) 2021-09-16
CN113966331B (zh) 2024-04-12

Similar Documents

Publication Publication Date Title
IL262139A (en) Bet protein degraders
JP2020517616A5 (zh)
CN113966331A (zh) 含脲结构的三芳环化合物及其应用
WO2016161361A4 (en) Compositions and methods of targeting mutant k-ras
RU2016118753A (ru) Производные пиридилкетона, способ их получения и их фармацевтическое применение
JP2008528467A5 (zh)
CN103403002A (zh) 作为激酶抑制剂的噻唑基苯基-苯磺酰氨基衍生物
JP2018516963A5 (zh)
CA2519898A1 (en) Oral administration of cyclic protein tyrosine kinase inhibitors
RU2015118647A (ru) Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr
JP2010539095A5 (zh)
JPWO2019191470A5 (zh)
WO2019024908A1 (zh) 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
KR20130029380A (ko) 메킬리아 락톤 유도체, 그 약제학적 조성물 및 그 제조방법과 용도
WO2017101791A1 (zh) 化合物及其在制备药物中的用途
CN109563091A (zh) Fgfr4抑制剂及其制备方法和应用
CN113906026A (zh) 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
KR20210053911A (ko) Ahr 조절제로서의 헤테로사이클릭 화합물
EP2615092A1 (en) Heterocyclic amino berbamine derivatives, preparation method and use thereof
CN113710671A (zh) 作为布鲁顿酪氨酸激酶抑制剂的环状分子
ES2325088T3 (es) Compuestos utiles en el tratamiento de hiv.
CN112771045A (zh) 喹啉并吡咯烷-2-酮类衍生物及其应用
CA2663965A1 (en) Pyrazolopyrimidine derivative and use thereof as an anticancer agent
CN111249283A (zh) 具有抗癌作用的嘧啶衍生物
CN115867539A (zh) 2,3-二氢-1H-吡咯并[3,2-b]吡啶衍生物、其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant